Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Lundbeck in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Lundbeck' s performance against key rivals in the ethical
pharmaceutical sector
- See how, driven by Cipralex and Lexapro royalties, Lundbeck will
outperform its peer set in the period to 2012
- Assess the company' s late-stage pipeline prospects following the setbacks
suffered by bifeprunox and desmoteplase and the abandonment of gaboxadol
View Cart
